Abstract Number: 494 • 2019 ACR/ARP Annual Meeting
Clinical and Biomarker Factor Associations with Symptoms and Future Development of RA: TIP-RA Collective
Background/Purpose: The Targeting Immune Responses for Prevention of RA (TIP-RA) Collaborative prospectively studies individuals at high risk for developing RA because of serum ACPA positivity…Abstract Number: 495 • 2019 ACR/ARP Annual Meeting
Pre-Rheumatoid Arthritis Diagnosis Prevalence of Commercial CCP Antibody Positivity Increases over Time with Strong Agreement Between Commercial Assays and Positivity Is Predicative of Developing Rheumatoid Arthritis Within 3 Years
Background/Purpose: Rheumatoid arthritis (RA) related autoantibodies, in particular antibodies to citrullinated proteins (ACPA), predict likelihood of developing future RA. Indeed, clinical trials for RA prevention…Abstract Number: 496 • 2019 ACR/ARP Annual Meeting
Assessment of Anti-Cyclic Citrullinated Protein and Connective Tissue Disease Screening Questionnaire in Healthy Adults from the Oklahoma Immune Cohort
Background/Purpose: Anti-CCP antibodies are present in the serum of healthy individuals who are at risk of developing RA and serve as an important tool for…Abstract Number: 497 • 2019 ACR/ARP Annual Meeting
Women with Rheumatoid Arthritis Have Higher Lifetime Occupational and Non-occupational Exposure to Silica Dust Compared to French General Population
Background/Purpose: Occupational exposure to silica dust is a well-known risk factor for ACPA positive rheumatoid arthritis (RA). The role of non-occupational exposure has not been…Abstract Number: 498 • 2019 ACR/ARP Annual Meeting
Should There Be Hierarchical Scoring Applied to Serologic Testing in the 2010 ACR/EULAR Classification Criteria?
Background/Purpose: The 2010 ACR/EULAR classification criteria for Rheumatoid Arthritis (RA) are based on a combination of clinical, laboratory, and imaging investigations. Positive serology contributes to…Abstract Number: 499 • 2019 ACR/ARP Annual Meeting
The Generation of Anti-CCP Tests Affects Diagnostic Accuracy in Rheumatoid Arthiritis: A Systematic Literature Review and Meta-Analysis
Background/Purpose: The detection of antibodies to cyclic citrullinated peptides (anti-CCP) may occur long before the onset of rheumatoid arthritis (RA) symptoms.Several versions of CCP antigen…Abstract Number: 500 • 2019 ACR/ARP Annual Meeting
The Dysregulation of NK Cells and Non-Conventional NK-T and γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis
Background/Purpose: The positivity of antibodies against citrullinated proteins (ACPA) precedes the clinical manifestation and significantly increases the risk of rheumatoid arthritis (RA). EULAR characterised individuals…Abstract Number: 501 • 2019 ACR/ARP Annual Meeting
EULAR Definition of “Arthralgia Suspicious for Progression to Rheumatoid Arthritis” in a Cohort of Patients Included in a Program for Rapid Diagnosis: Role of Ultrasound and Antibodies
Background/Purpose: To evaluate the performance of the EULAR definition of arthralgias suspicious for progression to rheumatoid arthritis (RA) in a group of patients admitted to…Abstract Number: 502 • 2019 ACR/ARP Annual Meeting
Disease Activity Measures at Baseline and 3 Months as Predictors of Rapid Radiographic Progression in Methotrexate Naïve Patients with Early Rheumatoid Arthritis
Background/Purpose: Progressive rheumatoid arthritis (RA) is responsible for disabilities in this patient population, characterized by radiographic joint damage. Achieving low disease activity (LDA) in RA…Abstract Number: 503 • 2019 ACR/ARP Annual Meeting
A Pilot Phase 1, Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P17 and Humira in Healthy Male Subjects
Background/Purpose: CT-P17 is a recombinant humanized monoclonal antibody that was developed as a biosimilar to the reference product, adalimumab. This was a first in human…Abstract Number: 504 • 2019 ACR/ARP Annual Meeting
A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis
Background/Purpose: RA patients who have failed biologic DMARDs represent an unmet medical need. We explored the impact of baseline demographics and clinical characteristics on filgotinib…Abstract Number: 505 • 2019 ACR/ARP Annual Meeting
Low-grade Total Rheumatoid Arthritis MRI Scoring System Can Predict Successful Half-dose Reduction of MTX in Patients with RA in Clinical Remission
Background/Purpose: It has been recommended that tapering csDMARDs should be considered if a patient is in persistent remission. However, methods for tapering csDMARDs, including MTX,…Abstract Number: 506 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results
Background/Purpose: Filgotinib (FIL) is an orally administered, potent and selective inhibitor of Janus kinase 1 (JAK1) that has shown good efficacy and was well tolerated…Abstract Number: 507 • 2019 ACR/ARP Annual Meeting
Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan
Background/Purpose: Peficitinib (PEF), a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in Phase 3 studies of patients with RA (NCT02305849).1 We report the…Abstract Number: 508 • 2019 ACR/ARP Annual Meeting
Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan
Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, demonstrated efficacy and an acceptable safety profile in a Phase 2b study (RAJ1 study, NCT01649999) and…
ACR Meeting Abstracts